issues

November/December 2023

Download PDF

COVER

2024 COMPANY PROFILES & CAPABILITIES

For each participating company, this section presents a detailed summary highlighting their core technologies, capabilities, technologies, and services.

FEATURES

2024 COMPANY PROFILES & CAPABILITIES

For each participating company, this section presents a detailed summary highlighting their core technologies, capabilities, technologies, and services.

FORMULATION FORUM – Nanosuspensions – An Enabling Formulation for Improving Solubility & Bioavailability of Drugs

Jim Huang, PhD, and Shaukat Ali, PhD, focus on the role of excipients and methods for preparation and application of nanosuspensions in injectable, ocular, topical, and oral drug delivery.

EXECUTIVE INTERVIEW – Lonza Small Molecules: Facing Up to the Challenges of Drug Development

Jan Vertommen, Lonza’s Head of Commercial Development (Small Molecules) discusses some of the challenges facing the sector and how his company is looking to address them.

PHARMACEUTICAL GLOBALIZATION – Navigating Opportunities & Obstacles

Jürgen Hönig says rapid globalization of the pharmaceutical industry has created new complexities as companies navigate different regulations and government policies, but there are many reasons for optimism, including harmonization, collaboration, and convergence.

CLOUD COMPUTING – Revolutionizing Antibody Discovery: The Role of Cloud Computing

Suhani Nagpal, PhD, Laura Spector, PhD, and Frank Erasmus, PhD, discuss the role of cloud computing in antibody discovery, its benefits, and its potential applications in the field of biotechnology.

DIGITALIZATION STRATEGIES – The Era of Technological Transformation in Pharma: Digitalization’s Role in Future-Proofing the Pharma & Biotech Industries

Kai Vogt says organizations that keep up with the technological transformation and incorporate employees in new digitalization strategies can likely achieve the greatest-possible success, which can be driven by the ability to produce high-quality drug products, and the commitment to reskilling employees, bringing human-centric value to an increasingly tech-driven industry.

EXECUTIVE INTERVIEW – Precision NanoSystems Inc. (part of Cytiva) & SCIEX: Lipid Impurities Within mRNA-LNPs

Kerstin Pohl, Senior Manager of Cell & Gene Therapy & Nucleic Acids at SCIEX, and Scott Ripley, General Manager of Nucleic Acid Therapeutics at Cytiva, dive into the detection of a new class of impurities within mRNA drugs and the impact it has on manufacturing.

LIPOSOMAL PEPTIDE THERAPEUTICS – Revolutionizing Oncology: Unleashing Innovative Strategies to Tackle Challenging, High-Value Drug Targets

Natalia Zisman, Krishna Allamneni, PhD, and Stacy W. Blain, PhD, explain how targeting downstream signaling proteins offers a promising approach to effectively mitigate the emergence of drug resistance that precision oncology therapies leave behind.

CARBOMER CHEMISTRY – Breaking Ground in Controlled Release

Nicholas DiFranco, MEM, believes by working alone or alongside other well-established excipients for controlled release such as HPMC, the power of carbomer chemistry can help drug developers to overcome common challenges associated with controlled-release formulations without resorting to more complex techniques.